Kun for helsepersonell

Dette nettstedet inneholder reklame for reseptpliktige legemidler og er kun for deg som er helsepersonell iht. Legemiddelforskriften § 13-1, dvs. lege, tannlege, offentlig godkjent sykepleier, farmasøyt, optiker, tannpleier, eller student i disse fagene.


JA, jeg er helsepersonell NEI, jeg er ikke helsepersonell

Forlater Chiesi-nettstedet...

Chiesi er ikke ansvarlig for informasjon på eksterne nettsider.

Vil du fortsette til ekstern nettside?

Ja Nei

Symposium

Forewarned is forearmed: cohort studies in the mission to understand structural and immunological determinants of early disease in chronic obstructive pulmonary disease

Speakers

Sonia Stajonevic, USA; Shawn Aaron, USA; Yunus Çolak, DK

Preterm birth and lifelong lung vulnerability

Preterm birth and the resulting disruption in lung development are well-recognized factors for early-onset COPD. However, as the lungs remain generally less complex structured, less vascularised, and with molecular and immunological differences compared to “normal” lungs, prematurely born may be predisposed for other diseases.1

While it has been shown in Nordic registry data that the more preterm a person was born, the higher the risk for disease, it remains unclear to what extent therapeutic measures early in life contribute to the development of diseases. Traditionally, patients in studies have been stratified based on presence or absence of bronchopulmonary dysplasia, BPD, but in the end, this is a proxy, highly affected by indication bias. As the definition of BPD varies across countries and over time, longitudinal data may not reflect the current clinical definitions, complicating interpretation of data. Moreover, the studies conducted investigate survivors of neonatal critical care – but who is missing from this data and what does it mean for our understanding of disease burden? When Professor Stajonevic presented her thoughts, she called for more modern statistical methods and to “leave kitchen sink regressions” behind. It is clear though that small lungs are more vulnerable to environmental exposure throughout life and should be carefully cared for by individuals born preterm and their healthcare providers.

Finding the undiagnosed: Screening versus case finding

A significant proportion of individuals (believed to be up to 70%) are undiagnosed and still fulfil the criteria for a COPD diagnosis. Professor Shawn Aaron presented two ways to find these persons, being screening measures or case finding activities.2,3 While screening would examine a proportion of the general population, case finding is a more targeted approach, e.g. by focusing on groups with higher risk, presence of symptoms or exposure. Persons could also fill in an online questionnaire and being provided the % probability of having a COPD or asthma diagnosis and with them, self-recruit themselves to proper medical investigation. With these methods, not only early or mild cases are found, but more than two thirds have sadly already progressed to a moderate and severe stage. Once identified, treatment according to latest guidelines showed better results than standard care in both COPD assessment tool, CAT, and St. George´s Respiratory Questionnaire.2

Tobacco Exposure: No Safe Threshold

Yunus Çolak reported data from the Copenhagen city heart study analysing tobacco exposure in relation to the risk of developing COPD.4 More than 20% of individuals with tobacco exposure below the threshold of 10 pack-years developed COPD. Clear reductions in total life expectancy of about 5 years were detected already with this low tobacco exposure. The risk does increase with increased tobacco exposure. The results were clear- there is no magic number of “pack-years” for low risk and good prognosis of COPD.

Barbara Fuchs
Medical Lead, Chiesi Nordic

References:

  1. Simpson SJ, Du Berry C, Evans DJ, Gibbons JTD, Vollsæter M, Halvorsen T, Gruber K, Lombardi E, Stanojevic S, Hurst JR, Um-Bergström P, Hallberg J, Doyle LW, Kotecha S; PELICAN. Unravelling the respiratory health path across the lifespan for survivors of preterm birth. Lancet Respir Med. 2024 Feb;12(2):167-180. doi: 10.1016/S2213-2600(23)00272-2. Epub 2023 Nov 14. PMID: 37972623.
  2. Aaron SD, Vandemheen KL, Whitmore GA, Bergeron C, Boulet LP, Côté A, McIvor RA, Penz E, Field SK, Lemière C, Mayers I, Bhutani M, Azher T, Lougheed MD, Gupta S, Ezer N, Licskai CJ, Hernandez P, Ainslie M, Alvarez GG, Mulpuru S; UCAP Investigators. Early Diagnosis and Treatment of COPD and Asthma – A Randomized, Controlled Trial. N Engl J Med. 2024 Jun 13;390(22):2061-2073. doi: 10.1056/NEJMoa2401389. Epub 2024 May 19. PMID: 38767248.
  3. Huynh C, Whitmore GA, Vandemheen KL, FitzGerald JM, Bergeron C, Boulet LP, Cote A, Field SK, Penz E, McIvor RA, Lemière C, Gupta S, Mayers I, Bhutani M, Hernandez P, Lougheed MD, Licskai CJ, Azher T, Ainslie M, Fraser I, Mahdavian M, Alvarez GG, Kendzerska T, Aaron SD. Derivation and validation of the UCAP-Q case-finding questionnaire to detect undiagnosed asthma and COPD. Eur Respir J. 2022 Sep 22;60(3):2103243. doi: 10.1183/13993003.03243-2021. PMID: 35332067.
  4. Çolak Y, Løkke A, Marott JL, Lange P, Vestbo J, Nordestgaard BG, Afzal S. Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study. Eur Respir J. 2024 Sep 12;64(3):2400314. doi: 10.1183/13993003.00314-2024. PMID: 38936967.

ID 17054 -03.10.2025